Woolcock Institute of Medical Research
Welcome,         Profile    Billing    Logout  
 1 Trial 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
King, Gregory J
PIANOFORTE, NCT04963140: Self-Management Of Asthma By Forced Oscillation Technique

Recruiting
N/A
200
Europe, RoW
Optimized self-management of asthma, Conventional self-management of asthma
Restech Srl
Asthma
04/24
09/24
Gordon, Christopher L
ExCEED, NCT05173844: Digital Sleep Therapy for Older Adults With Cognitive Impairment

Recruiting
N/A
128
RoW
SleepFix mobile application
Woolcock Institute of Medical Research
Insomnia Type; Sleep Disorder, Cognitive Impairment
08/24
12/24
ASTEROID, NCT05067569: App-delivered Sleep ThERapy for Older Individuals With Insomnia

Active, not recruiting
N/A
270
RoW
SleepFix mobile application, Sleep Health Education
Woolcock Institute of Medical Research, University of Sydney
Insomnia
05/24
05/24
SUCCEED, NCT05568381: Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention

Completed
N/A
40
RoW
digital CBT-I, Sleepio, Online Sleep Health Education package
University of Sydney
Cognitive Dysfunction, Insomnia, Mild Cognitive Impairment, Cognitive Disorder, Sleep Wake Disorders
08/23
11/23
SleepBack, NCT05846087: Mobile App-delivered Sleep Therapy (SleepFix) for Individuals With Chronic Low Back Pain and Insomnia

Recruiting
N/A
178
RoW
sleep retraining therapy, sleep restriction therapy, sleep consolidation therapy, sleep health education modules
Woolcock Institute of Medical Research, Cooperative Research Centre for Alertness, Safety and Productivity, University of Sydney
Chronic Low-back Pain, Insomnia
03/25
05/25
TREsh, NCT06686667: The Feasibility of Overnight Time Restricted Eating and Impact on Glucose Levels in Shift Workers

Not yet recruiting
N/A
30
NA
Time Restricted Eating
Woolcock Institute of Medical Research, South Eastern Sydney Local Health District
Shift Work, Eating Behaviors
04/25
05/25
Restless, NCT06567210: The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders

Not yet recruiting
N/A
110
RoW
CBCTi, General sleep information
Woolcock Institute of Medical Research, Macquarie University, Australia
Insomnia Chronic, Depression, Anxiety
06/27
06/29
SleepFix, NCT06114901: Efficacy of Mobile-delivered Sleep Restriction Therapy for Treatment of Insomnia Disorder: Randomised Controlled Trial

Not yet recruiting
N/A
558
RoW
SleepFix, Sleep health Education modules
Woolcock Institute of Medical Research
Insomnia
12/26
10/28
Yee, Brendon
CUPID, NCT05344170: Cannabinol Use in Patients With Insomnia Disorder

Completed
1/2
20
RoW
30 mg Cannabinol (CBN), ECS 310 (1.5%), 300 mg Cannabinol (CBN), ECS 310 (15%), Placebo
Woolcock Institute of Medical Research, University of Sydney
Insomnia Disorder
08/23
09/23
Grunstein, Ron
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
CANREST, NCT05253417: The CANabidiol Use for RElief of Short Term Insomnia

Completed
2
208
RoW
50 mg Cannabidiol (CBD), BodECS BioAbsorb(TM) capsule, Placebo, 100 mg Cannabidiol (CBD)
Bod Australia, Woolcock Institute of Medical Research
Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient, Insomnia Due to Anxiety and Fear, Insomnia Due to Other Mental Disorder
07/23
07/23
ACTRN12605000689673: An initial factorial evaluation of the potential synergy between two novel agents (CB0011 and CB0012) for the treatment of Obstructive Sleep Apnea Syndrome

Not yet recruiting
1/2
100
 
Cypress Bioscience, Inc, Cypress Biosince Inc.
Obstructive Sleep Apnea Syndrome
 
 
Mela-Nia, NCT06801379: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Pharmacokinetic Study

Not yet recruiting
1
5
RoW
Inhaled Melatonin (100 μg), Melatonin, N-Acetyl-5-methoxytryptamine, Oral Melatonin (4 mg), Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
Mela-Nia, NCT06802913: A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Efficacy Study

Not yet recruiting
1
10
RoW
Inhaled Melatonin (100 μg), Melatonin, Oral Melatonin (4 mg), N-Acetyl-5-methoxytryptamine, Circadin
Woolcock Institute of Medical Research
Insomnia
12/25
05/26
SUCCEED, NCT05568381: Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention

Completed
N/A
40
RoW
digital CBT-I, Sleepio, Online Sleep Health Education package
University of Sydney
Cognitive Dysfunction, Insomnia, Mild Cognitive Impairment, Cognitive Disorder, Sleep Wake Disorders
08/23
11/23
Restless, NCT06567210: The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders

Not yet recruiting
N/A
110
RoW
CBCTi, General sleep information
Woolcock Institute of Medical Research, Macquarie University, Australia
Insomnia Chronic, Depression, Anxiety
06/27
06/29
Palchick, Bryce
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Hartley, Paul
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
Grunstein, Ronald R
ASTEROID, NCT05067569: App-delivered Sleep ThERapy for Older Individuals With Insomnia

Active, not recruiting
N/A
270
RoW
SleepFix mobile application, Sleep Health Education
Woolcock Institute of Medical Research, University of Sydney
Insomnia
05/24
05/24
OLE, NCT05939141: An Extension Study to Assess the Long-term Safety of the Genio® System

Not yet recruiting
N/A
39
RoW
Genio System
Nyxoah S.A., Nyxoah Pty. Ltd.
Obstructive Sleep Apnea of Adult
07/28
07/28

Download Options